Trial Profile
A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval thiomersal-containing vaccines in young adult (18 to 60 years) and elderly subjects (over 60 years).
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 1536489A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline Biologicals; GSK
- 04 Aug 2011 New trial record